|Stanford University., B.A.|
Nina Kjellson is a General Partner at InterWest Partners and has been part of InterWest’s life sciences team since 2002, focusing primarily on investments in biopharmaceuticals. She is a board member of Alvine Pharmaceuticals, Cebix Pharmaceuticals, CNS Therapeutics, Inc., Eiger Biopharmaceuticals, Lycera, PrimeraDx, Sequel and Trius Therapeutics. Additionally, she is actively engaged with InterWest instment in APT an observer on its board. Prior to joining InterWest, Ms. Kjellson was an investment manager at Bay City Capital, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Ms. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation.